Genexine Stock

Genexine OCF Margin

The Operating Cash Flow Margin of Genexine (095700.KQ) as of Aug 5, 2026 is -646.81 %. In the previous year, Operating Cash Flow Margin was -56.21 % — a change of 1,050.75% (lower).

OCF Margin

-646.81 %

YoY

1,050.75%

Last updated:

Operating Cash Flow Margin of Genexine is 2026 -646.81 % . Operating Cash Flow Margin of Genexine was 2025 -56.21 % . It decreases by 1,050.75% lower compared to the previous year.
Access this data via the Eulerpool API

Genexine Stock analysis

What does Genexine do? Genexine Inc is a leading biotechnology company focused on developing therapies for serious diseases. The company was founded in Korea in 1999 and has since undergone impressive development. Genexine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genexine stock

Operating Cash Flow Margin of Genexine is -646.81 % in 2026.

Operating Cash Flow Margin of Genexine changed from -56.21 % to -646.81 %, representing a 1,050.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Genexine since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Genexine with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Genexine

All Key Metrics — Genexine